ライフサイエンスコーパス: brain tumor

1 erapy in glioblastoma, the most common adult brain tumor.

2 M) is the most common and aggressive primary brain tumor.

3 as a complication of intracranial surgery or brain tumor.

4 lastoma (MB) is a highly malignant pediatric brain tumor.

5 M) is the most common and aggressive type of brain tumor.

6 the most aggressive type of malignant human brain tumor.

7 M) is the most common and aggressive primary brain tumor.

8 oblastoma (GBM) is the most aggressive human brain tumor.

9 ressive and highly malignant type of primary brain tumor.

10 nt of Neurosurgery for surgical treatment of brain tumor.

11 Glioblastoma is a highly aggressive brain tumor.

12 a, one with pineal hemorrhage and one with a brain tumor.

13 ntial pitfall of (18)F-FET PET and may mimic brain tumor.

14 red directly in vivo in an established mouse brain tumor.

15 gnosis of patients undergoing craniotomy for brain tumor.

16 in up to one-third of patients with primary brain tumors.

17 nd for the delivery of chemotherapy drugs to brain tumors.

18 s well as in patients with untreated primary brain tumors.

19 or the first time the effect of oleandrin on brain tumors.

20 ted this hypothesis in vemurafenib-resistant brain tumors.

21 approaches to treat patients with malignant brain tumors.

22 exploit the vulnerabilities of GBM and other brain tumors.

23 is, although few in vivo data exist in human brain tumors.

24 rebellum, is among the most common pediatric brain tumors.

25 ghts into the pathogenesis of VTE in primary brain tumors.

26 aling in combination therapies for malignant brain tumors.

27 iple BRAF inhibitor resistance mechanisms in brain tumors.

28 tosolic IDH1 and mitochondrial IDH2 in human brain tumors.

29 s as well as in other varieties of pediatric brain tumors.

30 l nervous system tumors and 80% of malignant brain tumors.

31 diseases, including Alzheimer's disease and brain tumors.

32 mising boron delivery agents for the BNCT of brain tumors.

33 al disorders such as Alzheimer's disease and brain tumors.

34 ns resected from 12 patients with a range of brain tumors.

35 normal and pathological microenvironments in brain tumors.

36 to enhance the chemoresponsiveness of other brain tumors.

37 upts the BTB and enhances drug effusion into brain tumors.

38 cervical, esophageal, pancreatic, lung, and brain tumors.

39 loblastoma, one of the most common childhood brain tumors.

40 clinical trials in patients with BRAF(V600E) brain tumors.

41 ive impact of PBRT in survivors of pediatric brain tumors.

42 reatment outcomes of patients with malignant brain tumors.

43 ng, colon, pancreatic, melanoma, thyroid and brain tumors.

44 nmental factors on the etiology of childhood brain tumors.

45 drug resistance and retard the recurrence of brain tumors.

46 an reactivate an IDH1 mutant associated with brain tumors.

47 s (GBM) are highly radioresistant and lethal brain tumors.

48 e survival of mice bearing established GL261 brain tumors.

49 oliferation in neural precursor cells and in brain tumors.

50 h, and parental age were not associated with brain tumors.

51 resulting in 'ultra-hypermutated' malignant brain tumors.

52 orectal cancers, lymphomas or leukemias, and brain tumors.

53 Glioblastoma is one of the most aggressive brain tumors.

54 icytes to significantly improve treatment of brain tumors.

55 nsfer throughout highly disseminated primary brain tumors.

56 ing optimal surgical management of pediatric brain tumors.

57 taract and the stochastic risk of left-sided brain tumors.

58 scapes of human cancers, including childhood brain tumors.

59 e intraoperative diagnosis of pediatric type brain tumors.

60 ically active microenvironments in secondary brain tumors.

61 ing drug delivery and treatment for invasive brain tumors.

62 led to an evolution in the classification of brain tumors.

63 c opportunities to effectively treat primary brain tumors.

64 BRAF(V600E)mutations occur in many pediatric brain tumors.

65 the routine clinical classification of adult brain tumors.

66 Further, we find that lethal 3 malignant brain tumor 1 (L3MBTL1), a reader protein with chromatin

67 e isomerase (TPI1), and deleted in malignant brain tumors 1 protein (DMBT1).

68 1)C-AMT were obtained for mice bearing human brain tumors 1-7 d apart.

69 eated with cranial radiation treatment for a brain tumor (12.67 +/- 2.76 years), and 26 healthy child

70 sted in rats (n = 115), divided in 3 models: brain tumors (9 L, C6, F98), permanent stroke, and a con

71 exposure to ambient air toxics and childhood brain tumors: a population-based case-control study in C

72 w aberrant epigenetic pathways identified in brain tumors affect cell identity, cell state and neopla

73 emains the most common and deadliest type of brain tumor and contains a population of self-renewing,

74 is the most prevalent and malignant primary brain tumor and contains self-renewing, tumorigenic canc

75 lioblastoma (GBM) is the most common primary brain tumor and has a dismal prognosis.

76 lioblastoma (GBM) is the most lethal form of brain tumor and remains a large, unmet medical need.

77 Glioblastoma is the most aggressive primary brain tumor and responds poorly to currently available t

78 t a novel role for neurotrophin signaling in brain tumor and suggest that Trks could be a target for

79 most common and aggressive primary malignant brain tumor and the current standard-of-care therapeutic

80 and whole-brain irradiation, 19 with primary brain tumors and chemotherapy only, 52 with primary brai

81 for drug delivery in patients with malignant brain tumors and effectively facilitate BBB closure in n

82 cluding localization in the investigation of brain tumors and mobile phone use.

83 the central nervous system (CNS), including brain tumors and neurodegenerative diseases.

84 injured area in certain diseases, including brain tumors and neurodegenerative disorders.

85 Gliomas are the most common primary human brain tumors and occur in both adults and children.

86 delivery of therapeutic nucleic acids within brain tumors and provide a promising new delivery platfo

87 that have advanced the science of pediatric brain tumors and survival of patients with these tumors.

88 cortical stimulation (DCS) in patients with brain tumors and to assess factors associated with its a

89 When investigating the association between brain tumors and use of mobile telephones, accurate data

90 aging examinations (55 patients with primary brain tumors and whole-brain irradiation, 19 with primar

91 rs, 50% (six of 12) of patients with primary brain tumors, and 0% (zero of nine) of patients without

92 eningeal metastases, spine tumors, pediatric brain tumors, and meningiomas, as well as other clinical

93 mboembolism (VTE) is common in patients with brain tumors, and underlying mechanisms are unclear.

94 inical management of pediatric patients with brain tumors are discussed, as are recommendations for i

95 Malignant brain tumors are highly lethal and aggressive.

96 e tools for guiding therapy in children with brain tumors are urgently needed.

97 Gliomas, a common type of brain tumor, are characterized by aggressive infiltratio

98 current anatomic and physiologic imaging of brain tumors as a foundation for further investigations,

99 s can enhance the permeability of the BTB in brain tumors, as well as disrupting the BBB in the surro

100 Treatments of brain tumor associated edema with systemically delivered

101 y either had a prevalent meningioma or other brain tumor at the first CT examination or had undergone

102 residual or progressive benign or low-grade brain tumors at a single center between April 2001 to Ma

103 s and significantly prolongs the survival of brain tumor-bearing mice.

104 prominently dysregulated in high-grade glial brain tumors, blockade of PI3K or AKT minimally affects

105 Mutation of a single gene in Drosophila, Brain Tumor (Brat), leads to disrupted asymmetric cell d

106 ldhood acute lymphoblastic leukemia (ALL) or brain tumor (BT) with identified cognitive deficits were

107 mide is a DNA-alkylating agent used to treat brain tumors, but resistance to this drug is common.

108 an uptake and trapping in epileptic foci and brain tumors, but the short half-life of (11)C limits it

109 our understanding of the genetics of primary brain tumors by uncovering several novel driver genetic

110 Other therapeutic agents targeting brain tumor can be delivered locally in the brain to pro

111 e spectroscopy allows the differentiation of brain tumor cells from normal brain cells with a contras

112 ncy, and suppression of TMEM43 expression in brain tumor cells inhibited their growth both in vitro a

113 Brain tumor cells remain highly resistant to radiation a

114 particle diffusivity and increased uptake in brain tumor cells.

115 cell proliferation and promotes mortality of brain tumor cells.

116 Glioblastoma is an aggressive brain tumor characterized by an abnormal blood vasculatu

117 Glioblastoma multiforme (GBM) is a fatal brain tumor characterized by infiltration beyond the mar

118 Optic gliomas are brain tumors characterized by slow growth, progressive l

119 The new 2016 WHO brain tumor classification defines different diffuse gli

120 al nervous system primitive neuro-ectodermal brain tumors (CNS-PNETs) are rare tumors with ill-define

121 docrine tumors such as breast, prostate, and brain tumors concomitantly express several G protein-cou

122 were obtained in 33 children from Pediatric Brain Tumor Consortium clinical DIPG trials.

123 at 5 different institutions within the Adult Brain Tumor Consortium trial ABTC1101.

124 ients with recurrent HGG enrolled onto Adult Brain Tumor Consortium trials of single-agent, cytotoxic

125 hyl)-l-tyrosine ([(18)F]FET), in the delayed brain tumor (DBT) mouse model of high-grade glioma.

126 ew therapeutic approach for the treatment of brain tumors, demonstrating the potential of using the c

127 ing for patient age, gender and histological brain tumor diagnosis (beta = -0.253, p < 0.001).

128 e diagnostic reading of PET/MR patients with brain tumors did not change with the chosen AC method.

129 criptional disruptors in the fatal pediatric brain tumor, diffuse intrinsic pontine glioma (DIPG).

130 Conclusion High-grade pediatric brain tumors display higher CBF than do low-grade tumors

131 ioblastoma multiforme (GBM) is an aggressive brain tumor driven by cells with hallmarks of neural ste

132 of a workshop conducted by the Jumpstarting Brain Tumor Drug Development Coalition and the US Food a

133 ten ineffective in the treatment of invasive brain tumors due to poor therapeutic index.

134 have been reported for the major histologic brain tumor entities diagnosed in children, including in

135 We show that brain tumors escape pro-inflammatory M1 conversion of mi

136 of genetic and epigenetic events throughout brain tumor evolution.

137 ch, National Institutes of Health, Pediatric Brain Tumor Foundation, and the Garron Family Chair in C

138 mouse models of glioblastoma and metastatic brain tumors (from lung and breast cancer) were develope

139 The lethality of the aggressive brain tumor glioblastoma multiforme (GBM) results in par

140 mage-guided surgical resection of high-grade brain tumors (glioblastomas).

141 me are prone to the development of low-grade brain tumors (gliomas) within the optic pathway (optic g

142 lated with the DN:P ratio for the nontreated brain tumor group (P < .0001).

143 The radiation therapy-treated brain tumor group demonstrated higher DN:P ratios than t

144 than those in the radiation therapy-treated brain tumor group for doses greater than 20 (P = .05).

145 rated higher DN:P ratios than the nontreated brain tumor group for number of doses less than or equal

146 P < .0001), whereas ratios in the nontreated brain tumor group were higher than those in the radiatio

147 The GP:T ratios for the brain tumor groups were greater than that for the neurob

148 lutionarily conserved function for promoting brain tumor growth and metastasis, delineate downstream

149 n neuron survival, glial differentiation and brain tumor growth.

150 aerobic glycolysis, cell proliferation, and brain tumor growth.

151 We found that 32% of brain tumors had at least one ctDNA alteration.

152 Although bMMRD brain tumors had the highest mutational load because of

153 stic leukemia, hepatoblastoma, and malignant brain tumors had the highest risk of early death.

154 oblastoma, the most common primary malignant brain tumor, harbors a small population of tumor initiat

155 ation of developmental programs in malignant brain tumors has emerged as a driver for growth via canc

156 ain tumors, tissue heterogeneity in clinical brain tumors has not yet been fully evaluated with SRS i

157 Glioblastomas (GBM), deadly brain tumors, have greater incidence in males than femal

158 ing sarcomas, extracranial embryonal tumors, brain tumors, hematologic malignancies, carcinomas, and

159 Glioblastomas are the most common primary brain tumors, highly vascularized, infiltrating, and res

160 in our understanding of the common pediatric brain tumors (ie, medulloblastoma, low- and high-grade g

161 defined manually and automatically using the Brain Tumor Image Analysis (BraTumIA).

162 For brain tumor imaging (A and B), the standard PET-based di

163 )F]FAHep, (S)-[(18)F]15), were developed for brain tumor imaging and compared to the well-established

164 Food and Drug Administration, a standardized brain tumor imaging protocol now exists to reduce variab

165 ha,alpha-dialkyl substituted amino acids for brain tumor imaging.

166 Glioblastoma is the most aggressive primary brain tumor in adults and due to the invasive nature can

167 th glioma, the most common malignant primary brain tumor in adults, examination of cell-free DNA unco

168 oma (GBM), the most common primary malignant brain tumor in adults, remains a significant unmet need

169 is the most common and aggressive intrinsic brain tumor in adults.

170 stoma multiforme (GBM) remains the deadliest brain tumor in adults.

171 the most common and lethal primary malignant brain tumor in adults.

172 common and most aggressive malignant primary brain tumor in adults.

173 Medulloblastoma, the most common malignant brain tumor in children, is a biologically heterogeneous

174 r medulloblastoma, the most common malignant brain tumor in children, remains limited to surgical res

175 lloblastoma is the most common solid primary brain tumor in children.

176 Glioblastoma (GBM), the most aggressive brain tumor in human patients, is decidedly heterogeneou

177 There were 2,809 brain tumors in 69.7 million person-years of follow-up.

178 been made in this regard for common primary brain tumors in adults, especially diffuse gliomas, wher

179 r investigating genomic aspects of childhood brain tumors in both the research and the clinical setti

180 We examined risks for brain tumors in children after prenatal and infant expos

181 eling (ASL) data between low- and high-grade brain tumors in children to establish a cutoff to distin

182 bdoid tumor (ATRT) is one of the most common brain tumors in infants.

183 , 'sticky' microenvironment of the brain and brain tumors in particular.

184 ansgene expression throughout orthotopic rat brain tumors in vivo following administration by convect

185 p-ERK pathways are highly upregulated in the brain tumors, in alignment with their oncogenic activiti

186 born in Sweden in 1973-2008, followed up for brain tumor incidence through 2010 (maximum age 38 years

187 as observed in a significant number of human brain tumors including glioblastoma (n > 900) and correl

188 been implied as an oncogene which initiates brain tumors including glioblastomas.

189 utional phase II trial for localized primary brain tumors, including craniopharyngioma, ependymoma, a

190 usion, high podoplanin expression in primary brain tumors induces platelet aggregation, correlates wi

191 Brain tumor initiating cells (BTICs) co-opt the neuronal

192 Brain tumor initiating cells (BTICs), also known as canc

193 M) interactions modulate the galvanotaxis of brain tumor initiating cells (BTICs).

194 d in and has an important role in regulating brain tumor-initiating cells (BTIC) in GBM.

195 Oncogenic signaling by NOTCH is elevated in brain tumor-initiating cells (BTIC) in malignant glioma,

196 k metabolic dysregulation in patient-derived brain tumor-initiating cells (BTIC) to a nexus between M

197 CI, Xie et al. determined that GSI-resistant brain tumor-initiating cells (BTICs) from GBM express a

198 Brain tumor-initiating cells (BTICs) have been identifie

199 pt stem cell regulatory pathways to maintain brain tumor-initiating cells (BTICs), also known as canc

200 e importance of TrkB and TrkC in survival of brain tumor-initiating cells (BTICs).

201 rative DTI with image-guided sampling of the brain-tumor interface in 26 patients during resection of

202 When mice had two brain tumors, intratumoral VSV-LASV-GPC injection in one

203 treatment inhibited the growth of metastatic brain tumors introduced by intracardiac or intracranial

204 ecreased MMP2, a secreted proteinase key for brain tumor invasion.

205 Metabolic reprogramming in brain tumors is also influenced by the tumor microenviro

206 Drug delivery in brain tumors is challenging because of the presence of b

207 onformal radiotherapy techniques in treating brain tumors is largely based on data derived from dosim

208 ifications contribute to the pathogenesis of brain tumors is not well understood.

209 astoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic dive

210 ma, the most common and aggressive malignant brain tumor, is propagated by stem-like cancer cells ref

211 expression of TMEM43 closely correlates with brain tumor malignancy, and suppression of TMEM43 expres

212 The childhood brain tumor, medulloblastoma, includes four subtypes wit

213 Microglial cells in the brain tumor microenvironment are associated with enhance

214 we first developed a novel adult Drosophila brain tumor model using brat-RNAi driven by the neurobla

215 cell migration in vitro and in an orthotopic brain tumor model, in accordance with the known regulato

216 ioma-like tumors in an oncogene-driven mouse brain tumor model.

217 oaded in DNA-CN in two aggressive orthotopic brain tumor models in rats.

218 Primary brain tumors, most commonly gliomas, are histopathologic

219 ral nervous system (CNS) disorders including brain tumors, neurodegenerative diseases and psychiatric

220 most common and the most aggressive primary brain tumor of adults and children.

221 t medulloblastoma, the most common malignant brain tumor of childhood, is comprised of four disease v

222 ic resonance (MR) imaging characteristics of brain tumors on the functional MR imaging signal in the

223 on range in oncology, including treatment of brain tumors or CNS metastasis.

224 ic pediatric and adult gliomas and all other brain tumors (P < .001).

225 trapped by adhesion as they move through the brain tumor parenchyma.

226 esions alone has been insufficient to extend brain tumor patient survival.

227 We report changes in diagnosis for all brain tumor patients and the following relative differen

228 ments and promising preclinical experiments, brain tumor patients are still met with limited treatmen

229 signals.SIGNIFICANCE STATEMENT By comparing brain tumor patients to healthy children, we establish t

230 In the testing group (brain tumor patients), the sensitivity of the language m

231 ent, from recurrent tumors on T1-w MRI in 42 brain tumor patients, (2) different molecular sub-types

232 rom 33 prospectively enrolled pediatric type brain tumor patients, preserving tumor cytology and hist

233 le discharge outcome and shorter survival of brain tumor patients.

234 gical mapping and successfully applied it to brain tumor patients.

235 el of risk estimations for subpopulations of brain tumor patients.

236 demonstrated utility in the current care of brain tumor patients.

237 on for clinical decision making in pediatric brain tumor patients.

238 , are associated with systemic toxicities in brain tumor patients.

239 ively proliferating neuroblasts and a lethal brain tumor phenotype.

240 ritical roles in regulating neurogenesis and brain tumor progression.

241 astoma (GBM) is a prototypical heterogeneous brain tumor refractory to conventional therapy.

242 idual and/or progressive benign or low-grade brain tumors requiring radiotherapy for long-term tumor

243 uss how some of these genetic alterations in brain tumors rewire metabolism.

244 ific HuR protein multimerization in clinical brain tumor samples.

245 nstrate local therapeutic effects in treated brain tumor sections.

246 inform the surgical management of pediatric brain tumors.Significance: A new imaging method simplifi

247 ove chemotherapeutic responses in aggressive brain tumors.Significance: Combinatorial treatment of gl

248 agnetic field treatment successfully reduces brain tumor size and increases the survival rate of mice

249 tumoral platelet aggregates was performed in brain tumor specimens of 213 patients (mostly high-grade

250 tained from both animal xenografts and human brain tumor specimens.

251 entricle (LV) is a preferential location for brain tumor spread; however, the instructive cues respon

252 n factor STAT3 in mouse astrocytes and human brain tumor stem cells (BTSCs).

253 orty-nine PET/MRI brain scans were included: brain tumor studies using (18)F-fluoro-ethyl-tyrosine ((

254 d method for identifying language network in brain tumor subjects using ICA on rs-fMRI.

255 ajor obstacle for drug delivery to malignant brain tumors such as glioblastoma (GBM).

256 For patients with brain tumors, such inhibition protocols may ultimately b

257 The goal of brain tumor surgery is to maximize tumor removal without

258 nts (age 55.05 +/- 14.62 years) admitted for brain tumor surgery were evaluated for NT-proBNP serum c

259 and informs decision making during pediatric brain tumor surgery.

260 for, early endocrine disorders in childhood brain tumor survivors (CBTS).

261 advances that are being explored in current brain tumor targeted therapies, including local implant

262 rapidly being synthesized and tested as new brain tumor-targeted delivery strategies.

263 Gliomas are highly malignant brain tumors that are highly invasive and resistant to c

264 In the case of primary brain tumors that commonly affect adults, an emerging se

265 ly novel combination treatment for malignant brain tumors that includes focused ultrasound has been s

266 this safe, small molecule can contribute to brain tumor therapy and highlights the significance of H

267 ofibromatosis type 1 (NF1) develop low-grade brain tumors throughout the optic pathway.

268 ng nanoparticles" penetrate much deeper into brain tumor tissue compared to nanoparticles without a d

269 emic toxicity and inefficient penetration of brain tumor tissue even when it is placed directly in th

270 In a pediatric embryonal brain tumor tissue microarray, we observed an associatio

271 urine orthotopic xenografts models and human brain tumors, tissue heterogeneity in clinical brain tum

272 rate healthy brain parenchyma and orthotopic brain tumor tissues in rats.

273 We hypothesized that PID1 sensitizes brain tumors to therapy.

274 onment might affect the ability of malignant brain tumors to traverse between brain and vascular comp

275 for the other groups except for the group of brain tumors treated with chemotherapy (P < .05).

276 nt (IQ) over time in pediatric patients with brain tumors treated with PBRT versus XRT.

277 idual and/or progressive benign or low-grade brain tumors treated with SCRT and ConvRT techniques.

278 et to transform the therapeutic paradigm for brain tumor treatment.

279 r (BBB) poses the most significant hurdle to brain tumor treatment.

280 ore, of great interest in personalization of brain tumor treatment.

281 nogenic toxics, and estimated odds ratios by brain tumor type in logistic regression models.

282 dministration of GBCA occur in patients with brain tumors undergoing brain irradiation, as well as in

283 rotein, increases the risk of VTE in primary brain tumors via its ability to induce platelet aggregat

284 Brain tumor volume assessment is a major challenge.

285 on of tumor volume by PET of noninfiltrating brain tumors was accurate and reproducible.

286 y to improve the treatment of these invasive brain tumors, which are known to show high levels of the

287 lism can be leveraged to noninvasively image brain tumors, which facilitates improved diagnosis and t

288 mages in a cohort of patients with a primary brain tumor who had not received linear gadolinium-based

289 spective case-control study of children with brain tumors who underwent nine or more contrast materia

290 ) is the most common primary adult malignant brain tumor with poor prognosis.

291 lioblastoma (GBM) is a hypervascular primary brain tumor with poor prognosis.

292 Glioblastomas (GBMs) are malignant brain tumors with a median survival of less than 18 mont

293 glioma (HGG) is a group of primary malignant brain tumors with dismal prognosis.

294 are poorly understood and frequently lethal brain tumors with few treatment options.

295 Glioblastomas are extremely aggressive brain tumors with highly invasive properties.

296 esection of microscopic and low-grade glioma brain tumors with invasive or diffusive margins.

297 Pediatric embryonal brain tumors with multilayered rosettes demonstrate a un

298 stoma is the most common malignant pediatric brain tumor, with metastases present at diagnosis confer

299 = 4.5) in 238 children with newly diagnosed brain tumors, with independent replication in 68 similar

300 umors and chemotherapy only, 52 with primary brain tumors without any treatment, and 18 with neurobla